CLINICAL TRIAL: THALIDOMIDE IN THE TREATMENT OF WOMEN WITH CHRONIC PELVIC PAIN/E

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 中心，不一定是研究者的机构。 这是一项沙利度胺治疗与子宫内膜异位症相关的顽固性慢性盆腔疼痛的开放标签试验。受试者萨雷为不耐受或所有可用的常规药物治疗均失败的育龄妇女，子宫切除术是唯一的替代治疗方式。我们将招募17名患有顽固性疼痛的女性。入组前，我们将评估基线生活质量和疼痛水平。除了系列临床评估（每2-4周）外，我们还将监测活性药物治疗期间TNF α和白细胞介素水平的任何变化。在三个月的治疗结束时，治疗将终止。将在6个月时对受试者进行重新评估。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an open label trial of Thalidomide for treatment of intractable chronic pelvic pain associated with endometriosis. Participant sare reproductive age women who have been intolerant or have failed all available conventional medical therapies, with hysterectomy as the only alternative treatment modality. We will enroll 17 women with intractable pain. Prior to enrollment, we will assess baseline quality of life and pain level. In addition to serial clincial evaluation (every 2-4 weeks), we will monitor any changes in TNF alpha and interleukin level during the active drug treatment. At the end of the three month therapy, the treatment will be terminated. Subjects will be reassessed at 6 months.